GPR119 agonists for the treatment of type 2 diabetes (Q28259606)

From Wikidata

Jump to navigation Jump to search

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

scientific article

Language	Label	Description	Also known as
English	GPR119 agonists for the treatment of type 2 diabetes	scientific article

Statements

scholarly article

0 references

1 reference

Europe PubMed Central

GPR119 agonists for the treatment of type 2 diabetes (English)

0 references

type 2 diabetes

0 references

author name string

Robert M Jones

1

0 references

James N Leonard

2

0 references

Daniel J Buzard

3

0 references

Juerg Lehmann

4

0 references

language of work or name

0 references

publication date

October 2009

0 references

Expert Opinion on Therapeutic Patents

0 references

19

0 references

10

0 references

1339-59

0 references

A role for glucagon-like peptide-1 in the central regulation of feeding

1 reference

https://api.crossref.org/works/10.1517/13543770903153878

21 April 2017

Seven evolutionarily conserved human rhodopsin G protein-coupled receptors lacking close relatives

1 reference

https://api.crossref.org/works/10.1517/13543770903153878

21 April 2017

Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein-coupled receptor

1 reference

https://api.crossref.org/works/10.1517/13543770903153878

21 April 2017

Type 2 diabetes: principles of pathogenesis and therapy

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

21 January 2018

Type 2 diabetes: new genes, new understanding

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

21 January 2018

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

21 January 2018

Five stages of evolving beta-cell dysfunction during progression to diabetes

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

21 January 2018

The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

21 January 2018

Epidemiology and public health aspects of non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

21 January 2018

Diabetic retinopathy. A clinical overview

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

21 January 2018

Nephropathy in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

21 January 2018

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

21 January 2018

Standards of medical care in diabetes--2009.

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

21 January 2018

Pharmacotherapy for the treatment of patients with type 2 diabetes mellitus: rationale and specific agents

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

21 January 2018

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

21 January 2018

New hepatic targets for glycaemic control in diabetes

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

21 January 2018

The role of alpha-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

21 January 2018

MB06322 (CS-917): A potent and selective inhibitor of fructose 1,6-bisphosphatase for controlling gluconeogenesis in type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

21 January 2018

Inhibition of the protein tyrosine phosphatase PTP1B: potential therapy for obesity, insulin resistance and type-2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

21 January 2018

Modulation of glucocorticoid action and the treatment of type-2 diabetes

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

21 January 2018

Emerging therapeutic strategies for obesity

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

21 January 2018

Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

21 January 2018

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

21 January 2018

Biology of incretins: GLP-1 and GIP

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

21 January 2018

Signal transduction of PACAP and GLP-1 in pancreatic beta cells

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

21 January 2018

Characterization of GIP(1-30) and GIP(1-42) as stimulators of proinsulin gene transcription

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

21 January 2018

Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

21 January 2018

Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man.

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

21 January 2018

UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

21 January 2018

Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

21 January 2018

G protein-coupled receptors and insulin secretion: 119 and counting

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

21 January 2018

GPR119: "double-dipping" for better glycemic control

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

21 January 2018

A gut feeling for obesity: 7TM sensors on enteroendocrine cells

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

21 January 2018

GPR119 agonists as potential new oral agents for the treatment of type 2 diabetes and obesity

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

21 January 2018

GPR119, a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesity

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

21 January 2018

A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like Peptide-1 and glucose-dependent insulinotropic Peptide release

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

21 January 2018

Expression and distribution of Gpr119 in the pancreatic islets of mice and rats: predominant localization in pancreatic polypeptide-secreting PP-cells

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

21 January 2018

Discovery of the first potent and orally efficacious agonist of the orphan G-protein coupled receptor 119

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

21 January 2018

Gastric inhibitory polypeptide as an endogenous factor promoting new bone formation after food ingestion

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

21 January 2018

Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

21 January 2018

High throughput screening technologies for direct cyclic AMP measurement

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

21 January 2018

Identification of G protein-coupled receptor genes from the human genome sequence

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

21 January 2018

GPR119 is essential for oleoylethanolamide-induced glucagon-like peptide-1 secretion from the intestinal enteroendocrine L-cell

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

21 January 2018

Food intake regulates oleoylethanolamide formation and degradation in the proximal small intestine

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

21 January 2018

GPR119 is required for physiological regulation of glucagon-like peptide-1 secretion but not for metabolic homeostasis

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

21 January 2018

Gut hormone PYY(3-36) physiologically inhibits food intake

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

21 January 2018

Incretin-based therapies for type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

21 January 2018

Endogenous and synthetic agonists of GPR119 differ in signalling pathways and their effects on insulin secretion in MIN6c4 insulinoma cells

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

21 January 2018

The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

21 January 2018

Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

21 January 2018

Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

21 January 2018

Identifiers

10.1517/13543770903153878

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

PubMed publication ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28259606&oldid=1953554542"